J. van Dalem

First name
J.
Last name
van Dalem
van Dalem, J. ., Werkman, C. ., van den Bergh, J. P., Rossi, B. ., Viggers, R. ., Eastell, R. ., … Driessen, H. . (2022). "Use of sodium-glucose co-transporter 2 inhibitors, changes in body mass index and risk of fracture: a population-based cohort study". Diabetes Res Clin Pract, 109993. http://doi.org/10.1016/j.diabres.2022.109993
Knapen, L. M., van Dalem, J. ., Keulemans, Y. C., van Erp, N. P., Bazelier, M. T., De Bruin, M. L., … Driessen, J. H. (2016). Use of incretin agents and risk of pancreatic cancer: a population-based cohort study. Diabetes Obes Metab. http://doi.org/10.1111/dom.12605
van Dalem, J. ., Brouwers, M. C., Stehouwer, C. D., Krings, A. ., Leufkens, H. G., Driessen, J. H., … Burden, A. M. (2016). Risk of hypoglycaemia in users of sulphonylureas compared with metformin in relation to renal function and sulphonylurea metabolite group: population based cohort study. Bmj. http://doi.org/10.1136/bmj.i3625
van Dalem, J. ., Brouwers, M. ., Stehouwer, C. D. A., Krings, A. ., Klungel, O. H., Driessen, J. H. M., … Burden, A. M. (2018). Risk of a first-ever acute myocardial infarction and all-cause mortality with sulphonylurea treatment: A population-based cohort study. Diabetes Obes Metab. http://doi.org/10.1111/dom.13168
van Dalem, J. ., Driessen, J. H. M., Burden, A. M., Stehouwer, C. D. A., Klungel, O. H., de Vries, F. ., & Brouwers, M. . (2021). Thiazolidinediones and Glucagon-like Peptide-1 Receptor Agonists and the Risk of Nonalcoholic Fatty Liver Disease: A Cohort Study. Hepatology. http://doi.org/10.1002/hep.32012
van Dalem, J. ., Brouwers, C. ., Burden, A. M., C, D. A. S., Klungel, O. H., de Vries, F. ., & Driessen, H. . (2021). "Determinants of treatment modification before and after implementation of the updated 2015 NICE guideline on type 2 diabetes: a retrospective cohort study". Diabetes Res Clin Pract. http://doi.org/10.1016/j.diabres.2021.108828